智通财经APP获悉，艾迪康控股(09860)盘中涨近8%，截至发稿，涨5.17%，报7.53港元，成交额444.21万港元。
湘财证券指出，近期AI+医疗备受市场关注，AI广泛应用于医药领域，除了应用于诊疗领域还广泛应用于手术机器人、医疗影响设备、辅助药物设计及基因检测等领域。随着AI成熟度越来越高，其未来的应用场景和领域中也会出现更多的可能性，甚至可能会对一些行业造成颠覆性影响。该行提出，建议重点关注AI应用于临床诊断的相关ICL公司等。
公开资料显示，艾迪康控股是中国三大独立医学检验实验室(ICL)之一。公司在全国范围内拥有33家自营实验室，组成的集成网络为医院和体检中心提供4000多种检验服务。华创证券此前指出，国内ICL市场渗透率相较于国外仍有较大差距，在分级诊疗推进、医保控费压力加大、DRG/DIP付费方式改革、基层医疗建设的推动下，国内ICL行业有望进入快速发展期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.